Caplin Point Laboratories Limited Q4 Results 2026 Preview: Date, Time, Expectations & Key Things To Watch

Caplin Point Laboratories is a specialized pharmaceutical company with a dominant footprint in Latin American emerging markets and a rapidly expanding US injectable portfolio. Investors will be closely watching the company's margin sustainability as it navigates a 18-24 month gestation phase for new facilities and its ability to maintain its high-growth trajectory amid ongoing capacity expansion.

Caplin Point Laboratories Limited Q4 Results Date and Time

The board meeting is scheduled for May 14, 2026, to consider and approve annual audited financial results for the FY ended March 31, 2026, and to consider declaration of interim dividend for FY 2025-26.

What to expect from Caplin Point Laboratories Limited's Q4 FY26 results

In its most recently reported quarter, Caplin Point Laboratories posted revenue of Rs. 542.77 Crore, PAT of Rs. 165.86 Crore, and an EBITDA margin of 38.7%. The company is presently in an 18-24 month gestation phase for new market entries in Mexico, Chile, and Colombia, while maintaining a strong cash position of Rs. 1,381 Crore to fund ongoing capital expenditure. Management has reiterated a medium-term growth target of 20-25% from FY2028-29 onwards, supported by the recent receipt of four USFDA approvals between February and May 2026 totaling an addressable market of approximately $221 million. The upcoming results will likely focus on whether the company can maintain its PAT margin within the 26% to 29% target range during this consolidation period.

Key Things To Watch

Performance vs Guidance Tracking

• PAT Margin — 25% target — 28.5% achieved in 9M FY26
• Receivables — <120 days — 121 days currently
• US Business — High double-digit revenue growth — On track

Strategic execution and capex updates

• OSD Facility — Q3 FY27 completion — Revised from Q4 FY26
• Oncology API Facility — Thervoy facility — Operational within 9 months from early FY26
• Caplin One Lab — Early FY27 — Five lines target

Operating metric trajectory

• US Revenue — 25% YoY growth in 9M FY26 — Rs. 335 Crores
• ANDA Pipeline — 54 approved — 10 products under FDA review

Risks and headwinds to monitor

• OSD Facility Delay — Revised to Q3 FY27 due to cautious global environment
• Oncology Ecosystem — Talent availability challenges in Tamil Nadu